Sensus Healthcare (NASDAQ:SRTS) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Sensus Healthcare (NASDAQ:SRTS) announced its quarterly earnings results on Wednesday. The company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01), Zacks reports. Sensus Healthcare had a net margin of 22.54% and a return on equity of 17.99%.

Sensus Healthcare Stock Performance

Shares of NASDAQ:SRTS traded up $0.55 during trading on Wednesday, reaching $8.99. The stock had a trading volume of 715,614 shares, compared to its average volume of 271,054. Sensus Healthcare has a 1-year low of $2.91 and a 1-year high of $9.33. The stock has a market cap of $147.35 million, a PE ratio of 15.77 and a beta of 1.24. The business has a fifty day moving average price of $7.48 and a 200-day moving average price of $6.88.

Analyst Ratings Changes

Several brokerages recently weighed in on SRTS. Maxim Group lifted their price target on Sensus Healthcare from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Friday, November 15th. Lake Street Capital assumed coverage on Sensus Healthcare in a research note on Friday, January 31st. They set a “buy” rating and a $18.00 target price for the company. Finally, HC Wainwright lifted their price target on shares of Sensus Healthcare from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, November 18th.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.